<DOC>
	<DOCNO>NCT00781638</DOCNO>
	<brief_summary>Children age 18 year moderately active Ulcerative Colitis ( PUCAI:35-64 ) receive one weekly Adacolumn® apheresis treatment 5 consecutive week , follow 3 optional Adacolumn® apheresis treatment 3 consecutive week . Primary end point PUCAI Week 12 . The main part clinical investigation continue one year follow responder .</brief_summary>
	<brief_title>ADAPT Adacolumn Pediatric Trial Ulcerative Colitis</brief_title>
	<detailed_description>The individual clinical investigation period 12 week per patient . If patient take part follow , individual clinical investigation period 64 week . Patients receive one weekly Adacolumn® apheresis 5 consecutive week . The treat investigator may decide add 3 treatment base judgment . Treatment detail Day -07 : Screening ; Day 00 Baseline : 1st Adacolumn® apheresis ; Day 07 : 2nd Adacolumn® apheresis ; Day 14 : 3rd Adacolumn® apheresis ; Day 21 : 4th Adacolumn® apheresis ; Day 28 : 5th Adacolumn® apheresis ; Week 12 : Final evaluation</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>1 . Children adolescents &lt; 18 year 2 . Ulcerative colitis document clinical symptom , endoscopic finding histology ( patient history ) 3 . Moderate active ulcerative colitis baseline evaluation , define follow : PUCAI 35 64 4 . Pancolitis leftsided colitis 5 . Ulcerative colitis least 3 month 6 . Receiving receive one follow medicinal product screen : Sulfasalazine , mesalamine 5aminosalicylic acid ( 5ASA ) agent 4 week stable dose last 2 week , 0.5mg/kg/body weight maximum 20 mg per day prednisone stable dose last 2 week , 6mercaptopurine azathioprine 12 week stable dose last 4 week Other UC medication allow ( see also Chapter 4.4.2 ) . 7 . For female patient childbearing potential , negative pregnancy test agreement use effective contraceptive method abstain sexual activity course clinical investigation 8 . Agreement participate visit 9 . Signed write informed consent document patient legal guardian representative 10 . Body weight must equal 30kg 11 . Adequate peripheral venous access allow completion apheresis treatment 1 . Febrile ( &gt; 38ºC ) 2 . Evidence toxic megacolon 3 . Anticipated need surgery within 12 week Day 00 4 . Major surgery within past 6 week 5 . Known obstructive disease gastrointestinal system 6 . Proctocolectomy , total colectomy , ileostomy , stoma ileal pouchanal anastomosis 7 . A history allergic reaction heparin heparininduced thrombocytopenia 8 . A history hypersensitivity reaction associate apheresis procedure intolerance apheresis procedures 9 . Known infection enteric pathogen , pathogenic ovum parasite , positive assay C. difficile toxin 10 . Symptomatic hypotension 11 . Pediatric heart condition problem high susceptibility thrombotic event ( e.g . valve defect similar ) 12 . A history physical finding compatible cerebrovascular accident 13 . Prosthetic heart valve , pacemaker permanent implant 14 . Severe cardiovascular peripheral vascular disease 15 . Liver disease defined level GOT [ AST ] , GPT [ ALT ] alkaline phosphatase &gt; 2.5x upper limit normal range laboratory perform test 16 . History cirrhosis 17 . Renal insufficiency , define serum creatinine &gt; 150 % upper limit normal range laboratory perform test 18 . Known bleed disorder ( PT PTT &gt; 1.5x upper limit normal range laboratory perform test ) , concomitant anticoagulant therapy purpose apheresis treatment 19 . Prior history suggestive hypercoagulable disorder , include 1 episode pulmonary embolism deep vein thrombosis 20 . Known infection Hepatitis B C , HIV 21 . Abnormal hematology parameter define severe anemia hemoglobin &lt; 8.5g/dL , white blood cell count &lt; 3,500/μl granulocyte count &lt; 2,000/μl 22 . Fibrinogen level &gt; 700mg/dL 23 . Infection : Active infection successful completion antibiotic treatment routine bacterial infection le 4 week entry clinical investigation ( screen ) Febrile viral infection within 4 week entry clinical investigation ( screen ) Less 12 week conclusion therapy systemic fungal infection screen 24 . Malignancy within past 2 year surgically cure skin carcinoma cervical dysplasia ( CIN III ) 25 . History dysplasia carcinoma colon 26 . Current drug alcohol abuse 27 . Pregnant , lactate plan become pregnant course clinical investigation 28 . Used within last 30 day investigational medicinal product , biologic device 29 . Pretreatment UC drug 5ASA derivative , azathioprine corticosteroid , e.g . immunosuppressant biologics 30 . Steroidresistance dependency , define inability completely withdraw steroid without induce relapse flareup disease 31 . Topical therapy ulcerative colitis within last 2 week .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Pediatric UC , Adacolumn apheresis</keyword>
</DOC>